3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
8
Breast
3
Other
2
Tumor-Agnostic
1
Lymphoid
1
Endocrine
1
Conditions
Sexuality
1
Neoplasms
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Hypogonadism
1
Interventions
Rituximab
702
Cyclophosphamide
643
Vincristine
352
Doxorubicin
307
Etoposide
303
Cytarabine
270
Filgrastim
250
Prednisone
248
Methotrexate
240
fludarabine phosphate
231
Dexamethasone
208
fludarabine
183
Peripheral Blood Stem Cell Transplantation
165
Radiotherapy
160
Granulocyte Colony-Stimulating Factor
145
Lenalidomide
144
Bendamustine Hydrochloride
142
Bortezomib
127
Melphalan
126
ibrutinib
111
Busulfan
110
Mycophenolic Acid
107
Whole-Body Irradiation
106
Tacrolimus
96
Cyclosporine
86
Gemcitabine
82
Ifosfamide
80
Alemtuzumab
80
Calcium Dobesilate
79
Leucovorin
77
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Testosterone
×
Lymphoid
×
Clear all
NCT04492553
2022-11-29
Vitality
Herlev Hospital
Phase 2
Completed
7 enrolled